Democratic senators demand answers on Novo Nordisk's discontinued insulin

A trio of Democratic senators want Novo Nordisk to explain why it discontinued one of its long-acting insulin products after it announced a steep price cut on the medication.

Sens. Jeanne Shaheen (N.H.), Raphael Warnock (Ga.) and Elizabeth Warren (Mass.) wrote to Novo Nordisk CEO Lars Fruergaard Jørgensen and head of North American operations Doug Langa.

Last year, Novo Nordisk announced it would cut the prices of some of its insulin products, including cutting the price of Levemir by 65 percent.